Canine PD-L1 antibody, antigen binding fragments thereof, and methods of use thereof
AssigneePurdue Research Foundation
InventorsDeborah Knapp, Deepika Dhawan, Seung-Oe Lim, Perry Kirkham
Life of this patent
Estimating the term…
Abstract
Caninized antibodies and antigen binding fragments thereof are provided that bind programmed death ligand 1 in a canine subject. Methods of treating cancer in a canine subject using the caninized antibodies and/or antigen binding fragments are also provided, as are methods for predicting and modeling anti-cancer activity of a test compound in a subject.
Claims12
An antibody or antigen binding fragment thereof that binds canine programmed death ligand 1 (PD-L1) in a canine subject with specificity, wherein the antibody or antigen binding fragment comprises a light chain and a heavy chain, wherein the light chain comprises amino acid residues 21-243 of SEQ ID NO:
- 27,
- and wherein the heavy chain comprises amino acid residues 20-472 of SEQ ID NO:
- 3.
A pharmaceutical composition comprising an antibody or antigen binding fragment thereof and a pharmaceutically acceptable excipient, wherein the antibody or antigen binding fragment comprises a light chain and a heavy chain, wherein the light chain comprises amino acid residues 21-243 of SEQ ID NO:
- 27,
- and wherein the heavy chain comprises amino acid residues 20-472 of SEQ ID NO:
- 3.
Dependencies are inferred from the claim text.